ArticleActa neuropathologica communications2025
Alpha 9 integrin in spinal cord repair: a critical appraisal of mechanisms, circuitry, and translational potential.
Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In response to the groundbreaking study by Stepankova et al. (Acta Neuropathol Commun 13:89, 2025) demonstrating that activated α9 integrin enables sensory axon regeneration after spinal cord injury, this letter provides a critical perspective on the mechanistic underpinnings and translational implications of their findings. While acknowledging the significance of identifying α9 integrin as a potent pro-regenerative driver, we highlight several areas requiring deeper investigation. Specifically, we interrogate the precise ligand-receptor interactions within the inhibitory injury environment and potential crosstalk with inhibitory signaling pathways. Furthermore, we raise critical concerns regarding the long-term stability and functional specificity of the regenerated sensory circuits, emphasizing the risk of maladaptive synaptogenesis leading to neuropathic pain. Finally, we contextualize these findings within the challenges of clinical translation, arguing that the efficacy of this approach must be validated in more severe, contusive injury models that better recapitulate the human pathology. This critical analysis aims to frame the essential next steps required to transform this compelling biological discovery into a viable therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.